Page 12 - Cassava Sciences News Today

Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD...

Cassava Sciences, Inc. SAVA shares are trading higher after the company announced MRI data suggested simufilam is not associated with amyloid-related imaging…

NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc.  . Such investors are advised to contact Robert S. Willoughby at...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such...

Let's unpack Wegovy's inconsistent results, BrainStorm Cell Therapeutics' FDA withdrawal, and Nkarta's successful pivot.

This past week in healthcare investigations

ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ:...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

A researcher whose work was integral to the development of the Alzheimer’s drug simufilam has been found by the City University of New York to have engaged in “egregious misconduct” involving more than 20 scientific papers, Science reported.

American investors have been taken for a trillion-dollar ride by naked short sellers, in what could turn out to be the biggest financial regulatory scandal in North American history